This website is no longer being updated. Please visit GBCHealth’s new website at: www.gbchealth.org.

This panel discussion is part of a critical effort to help the people of Hawaii understand the risks associated with CHB and the importance of early diagnosis. Once diagnosed with CHB, patients need to be linked to care, evaluation and treatment.

08/08/2013

NEWS

Bristol-Myers Squibb Panel Addresses Hepatitis B Problem in Hawaii

GBCHealth member Bristol-Myers Squibb (BMS), the Hawaii State Department of Health and Viral Hepatitis Action Coalition (VHAC), a partner of the Centers for Disease Control Foundation, convened leading community experts to discuss key barriers to the diagnosis and treatment of Chronic Hepatitis B (CHB) in Hawaii.

Around 65 percent of Americans infected with the hepatitis B virus are unaware of their status, and in Hawaii, the local department of health estimates that only 1 percent of the estimated 40,000 people living with it know their status. One in 12 Asian Americans has CHB, which can lead to serious health complications and liver disease.

The forum, which included Asian-American physicians who specialize in the management of CHB and community advocates, was a joint effort to support early disease identification and to connect at-risk patients to necessary care. THe event was pegged to World Hepatitis Day on July 28th.

BMS has awarded the CDC Foundation a grant to help support early hepatitis B disease identification and connect patients to necessary care.

“This panel discussion is part of a critical effort to help the people of Hawaii understand the risks associated with CHB and the importance of early diagnosis. Once diagnosed with CHB, patients need to be linked to care, evaluation and treatment,” said Carol L. Brosgart, M.D., senior advisor on science and policy, VHAC, at the CDC Foundation.

Read more

ASSOCIATED CONTENT